HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $41 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on TG Therapeutics (NASDAQ:TGTX) and maintained a price target of $41.
September 18, 2023 | 10:27 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TG Therapeutics (NASDAQ:TGTX) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $41.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for TG Therapeutics. The maintained price target of $41 indicates the firm's continued confidence in the stock's potential, which could positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100